Under which conditions is medicinal product advertising authorized in France? Is the advertising of medicinal products benefiting from derogatory access, such as early access and compassionate access resulting from the July 2021 reform, authorized? What are the specificities to be taken into account for the advertising of medicinal products on the Internet? What benefits can pharmaceutical companies grant to healthcare professionals under the new “anti-gift” scheme and under what conditions? What agreements must manufacturers make public under the “transparency” scheme ?
Here are some of the issues addressed in the France Chapter of the Chambers Guide to Drug Advertising, which we are pleased to make available to you again this year.
The purpose of this Guide, written in English, is to set out in a comprehensive and synthetic manner all the national regulations and good practices relating to the advertising of medicinal products and the rules governing relations with the industry.
